These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 21885241

  • 1. Delayed immune-mediated thrombocytopenia after re-exposure to abciximab therapy.
    Rasti M, Blostein M.
    Can J Cardiol; 2011; 27(6):869.e13-4. PubMed ID: 21885241
    [Abstract] [Full Text] [Related]

  • 2. Acute profound thrombocytopenia without bleeding complications after re-administration of abciximab.
    Nguyen N, Salib H, Mascarenhas DA.
    J Invasive Cardiol; 2001 Jan; 13(1):56-8. PubMed ID: 11146690
    [Abstract] [Full Text] [Related]

  • 3. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, eptifibatide and abciximab: outcomes, complications and thrombocytopenia during percutaneous coronary intervention.
    Suleiman M, Gruberg L, Hammerman H, Aronson D, Halabi M, Goldberg A, Grenadier E, Boulus M, Markiewicz W, Beyar R.
    J Invasive Cardiol; 2003 Jun; 15(6):319-23. PubMed ID: 12777670
    [Abstract] [Full Text] [Related]

  • 4. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.
    Topol EJ, Moliterno DJ, Herrmann HC, Powers ER, Grines CL, Cohen DJ, Cohen EA, Bertrand M, Neumann FJ, Stone GW, DiBattiste PM, Demopoulos L, TARGET Investigators. Do Tirofiban and ReoPro Give Similar Efficacy Trial.
    N Engl J Med; 2001 Jun 21; 344(25):1888-94. PubMed ID: 11419425
    [Abstract] [Full Text] [Related]

  • 5. Readministration of abciximab in percutaneous coronary intervention.
    Fry ET.
    J Invasive Cardiol; 1999 Apr 21; 11(4):251-8. PubMed ID: 10745525
    [Abstract] [Full Text] [Related]

  • 6. Abciximab-associated thrombocytopenia after previous tirofiban-related thrombocytopenia.
    Dorsch MP, Montague D, Rodgers JE, Patterson C.
    Pharmacotherapy; 2006 Mar 21; 26(3):423-7. PubMed ID: 16503724
    [Abstract] [Full Text] [Related]

  • 7. Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting.
    Merlini PA, Rossi M, Menozzi A, Buratti S, Brennan DM, Moliterno DJ, Topol EJ, Ardissino D.
    Circulation; 2004 May 11; 109(18):2203-6. PubMed ID: 15117843
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Acute profound thrombocytopenia following abciximab therapy.
    Bishara AI, Hagmeyer KO.
    Ann Pharmacother; 2000 May 11; 34(7-8):924-30. PubMed ID: 10928405
    [Abstract] [Full Text] [Related]

  • 11. Acute profound thrombocytopenia without bleeding complications after abciximab administration.
    Elmi F, Oza R, Mascarenhas DA.
    J Invasive Cardiol; 1999 May 11; 11(5):313-5. PubMed ID: 10745539
    [Abstract] [Full Text] [Related]

  • 12. Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
    Tcheng JE, Kandzari DE, Grines CL, Cox DA, Effron MB, Garcia E, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Fahy M, Lansky AJ, Mehran R, Stone GW, CADILLAC Investigators.
    Circulation; 2003 Sep 16; 108(11):1316-23. PubMed ID: 12939213
    [Abstract] [Full Text] [Related]

  • 13. Abciximab readministration.
    Orford JL, Holmes DR.
    Rev Cardiovasc Med; 2002 Sep 16; 3(2):67-70. PubMed ID: 12447149
    [Abstract] [Full Text] [Related]

  • 14. Thrombocytopenia associated with c7E3 Fab (abciximab).
    Schell DA, Ganti AK, Levitt R, Potti A.
    Ann Hematol; 2002 Feb 16; 81(2):76-9. PubMed ID: 11907786
    [Abstract] [Full Text] [Related]

  • 15. Abciximab-induced delayed profound thrombocytopaenia.
    Jbara M, Bhogal S, Bajaj K, Chhabra L.
    BMJ Case Rep; 2017 Jun 02; 2017():. PubMed ID: 28576909
    [Abstract] [Full Text] [Related]

  • 16. Reversal of recurrent thrombocytopenia due to abciximab.
    Sharma V, Mascarenhas D.
    J Invasive Cardiol; 2004 Sep 02; 16(9):537-8. PubMed ID: 15353816
    [No Abstract] [Full Text] [Related]

  • 17. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel.
    Mehilli J, Kastrati A, Schühlen H, Dibra A, Dotzer F, von Beckerath N, Bollwein H, Pache J, Dirschinger J, Berger PP, Schömig A, Intracoronary Stenting and Antithrombotic Regimen: Is Abciximab a Superior Way to Eliminate Elevated Thrombotic Risk in Diabetics (ISAR-SWEET) Study Investigators.
    Circulation; 2004 Dec 14; 110(24):3627-35. PubMed ID: 15531766
    [Abstract] [Full Text] [Related]

  • 18. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.
    Lincoff AM, Califf RM, Moliterno DJ, Ellis SG, Ducas J, Kramer JH, Kleiman NS, Cohen EA, Booth JE, Sapp SK, Cabot CF, Topol EJ.
    N Engl J Med; 1999 Jul 29; 341(5):319-27. PubMed ID: 10423466
    [Abstract] [Full Text] [Related]

  • 19. A case of pseudothrombocytopenia after infusion of abciximab in vivo and anticoagulant-independent platelet clumping after rechallenge with abciximab in vitro.
    Kozak M, Dovc T, Rozman P, Blinc A.
    Wien Klin Wochenschr; 2000 Feb 11; 112(3):138-41. PubMed ID: 10729966
    [Abstract] [Full Text] [Related]

  • 20. Introduction: glycoprotein IIb/IIIa blockers in the era of metallic coronaries.
    Goldschmidt-Clermont PJ.
    J Invasive Cardiol; 2002 Dec 11; 14 Suppl E():1E. PubMed ID: 12668856
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.